Flupirtine
General information:
| Withdrawn ID: | DB06623 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | N02BG07 |
| Molecular Formula: | C15H17FN4O2 |
| Molweight: | 304.32 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First withdrawn: | 2018 |
| Reference: | https://www.ema.europa.eu/en/news/withdrawal-pain-medicine-flupirtine-endorsed |
Side-effects:
| Total reported cases (submitted by medical professionals) with Flupirtine as primary suspect: | 3 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 3 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| Drug-induced liver injury | 2 |
| DRUG INTERACTION | 1 |
| HEPATIC ENZYME INCREASED | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P19838 | 28.2 | Nuclear factor NF-kappa-B p105 subunit | NFKB1_HUMAN |
| P34897 | 933.25 | Serine hydroxymethyltransferase, mitochondrial | GLYM_HUMAN |
| P55210 | 10000 | Caspase-7 | CASP7_HUMAN |
| Q16665 | 3981.1 | Hypoxia-inducible factor 1-alpha | HIF1A_HUMAN |
Toxicity information:
External links:
| ChEBML: | CHEMBL255044 |
|---|